Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755

Pattern Recognition Receptors and Inflammation

Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056

Taking dendritic cells into medicine

Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,162

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747

HMGB1 is a therapeutic target for sterile inflammation and infection

Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437

Research progress on morphology and mechanism of programmed cell death

Chen, Y., Li, X., Yang, M., & Liu, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06712-8 · Cited by 168

TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression

Vidyarthi, A., Khan, N., Agnihotri, T., Negi, S., Das, D. K., Aqdas, M., Chatterjee, D., Colegio, O. R., Tewari, M. K., & Agrewala, J. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01650 · Cited by 163

Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death

Asadzadeh, Z., Safarzadeh, E., Safaei, S., Baradaran, A., Mohammadi, A., Hajiasgharzadeh, K., Derakhshani, A., Argentiero, A., Silvestris, N., & Baradaran, B. (2020) · Cancers · doi:10.3390/cancers12041047 · Cited by 158

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy

Akalu, Y. T., Rothlin, C. V., & Ghosh, S. (2017) · Immunological Reviews · doi:10.1111/imr.12522 · Cited by 158

Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance

Tang, R., Rangachari, M., & Kuchroo, V. K. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101302 · Cited by 156

Inhibitory receptors as targets for cancer immunotherapy

Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 157

Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors

Lin, A. G., Xiang, B., Merlino, D. J., Baybutt, T. R., Sahu, J., Fridman, A., Snook, A. E., & Miller, V. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484978 · Cited by 156

Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy

Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 159

Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes

Zakharov, P. N., Hu, H., Wan, X., & Unanue, E. R. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192362 · Cited by 149

The Tumor Microenvironment: A Pitch for Multiple Players

Schiavoni, G., Gabriele, L., & Mattei, F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00090 · Cited by 147

Not All Immune Checkpoints Are Created Equal

Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 157

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice

Lasorsa, F. M., di Meo, N. A., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S. D., Crocetto, F., Tătaru, O. S., Riccardo Autorino, B., Battaglia, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11041071 · Cited by 146

High-mobility group box family of proteins: ligand and sensor for innate immunity

Yanai, H., Ban, T., & Taniguchi, T. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.10.005 · Cited by 146

The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia

Koh, H. S., Chang, C. Y., Jeon, S.-B., Yoon, H. J., Ahn, Y.-H., Kim, H.-S., Kim, I.-H., Jeon, S. H., Johnson, R. S., & Park, E. J. (2015) · Nature Communications · doi:10.1038/ncomms7340 · Cited by 141

T Cell Ig Mucin-3 Promotes Homeostasis of Sepsis by Negatively Regulating the TLR Response

Yang, X., Jiang, X., Chen, G., Xiao, Y., Geng, S., Kang, C., Zhou, T., Li, Y., Guo, X., He, X., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202661 · Cited by 139

Tim-3, Lag-3, and TIGIT

Joller, N., & Kuchroo, V. K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_62 · Cited by 145

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

Sauer, N. J., Janicka, N., Szlasa, W., Skinderowicz, B., Kołodzińska, K., Dwernicka, W., Oślizło, M., Kulbacka, J., Novickij, V., & Karłowicz-Bodalska, K. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03516-1 · Cited by 142

Checkpoint inhibitors in hematological malignancies

Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 139

Tim-3 expression and its role in hepatocellular carcinoma

Liu, F., Liu, Y., & Chen, Z. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0667-4 · Cited by 138

Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy

Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 138

Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies

Gebremeskel, S., & Johnston, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6113 · Cited by 139

STING, DCs and the link between innate and adaptive tumor immunity

Vatner, R. E., & Janssen, E. M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.001 · Cited by 139

Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors

Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 137

Mechanisms of Regulated Cell Death: Current Perspectives

Santagostino, S. F., Assenmacher, C., Tarrant, J. C., Adedeji, A. O., & Radaelli, E. (2021) · Veterinary Pathology · doi:10.1177/03009858211005537 · Cited by 137

Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases

Chen, R., Hou, W., Zhang, Q., Kang, R., Fan, X., & Tang, D. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00099 · Cited by 130

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death

Vaes, R. D. W., Hendriks, L. E. L., Vooijs, M., & Ruysscher, D. D. (2021) · Cells · doi:10.3390/cells10040930 · Cited by 134

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126

Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses

Mandke, P., & Vásquez, K. M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102701 · Cited by 126

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

Long noncoding RNAs in cancer‐immunity cycle

Yu, W., Wang, H., He, Q., Xu, Y., & Wang, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26568 · Cited by 124

The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells

Hajihosseini, R., Asef‐Kabiri, L., Yousefi, H., Sarvnaz, H., Salehi, M., Akbari, M. E., & Eskandari, N. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01376-w · Cited by 123

The dual role and therapeutic potential of high-mobility group box 1 in cancer

He, S.-J., Cheng, J. Q., Xiao, F., Yu, Y., Tian, L., & Huang, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17885 · Cited by 126

TIM-3 Regulates Distinct Functions in Macrophages

Ocaña‐Guzmán, R., Torre-Bouscoulet, L. I., & Sada‐Ovalle, I. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00229 · Cited by 122

Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing

Garg, A. D., Vandenberk, L., Fang, S., Fasche, T., Van Eygen, S., Maes, J., Van Woensel, M., Koks, C., Vanthillo, N., Graf, N., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.15 · Cited by 120

Rethinking immune checkpoint blockade: ‘Beyond the T cell’

Liu, X., Hogg, G. D., & DeNardo, D. G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001460 · Cited by 123

TKIs in combination with immunotherapy for hepatocellular carcinoma

Stefanini, B., Ielasi, L., Chen, R., Abbati, C., Tonnini, M., Tovoli, F., & Granito, A. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2181162 · Cited by 120

Immune checkpoint blockade opens a new way to cancer immunotherapy

Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 119

Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside

Yin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 122

Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy

Sabatos-Peyton, C. A., Nevin, J. T., Brock, A., Venable, J. D., Tan, D. J., Kassam, N., Xu, F., Taraszka, J. A., Wesemann, L. D., Pertel, T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1385690 · Cited by 118

Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients

Liu, Z., McMichael, E. L., Shayan, G., Li, J., Chen, K. C., Srivastava, R. M., Kane, L., Lu, B., & Ferris, R. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1350 · Cited by 121

The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas

Komohara, Y., Morita, T., Annan, D. A., Horlad, H., Ohnishi, K., Yamada, S., Nakayama, T., Kitada, S., Suzu, S., Kinoshita, I., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0156 · Cited by 116

Tumor immunity times out: TIM-3 and HMGB1

Tang, D., & Lotze, M. T. (2012) · Nature Immunology · doi:10.1038/ni.2396 · Cited by 116

Type I Interferon Production of Plasmacytoid Dendritic Cells under Control

Bencze, D., Fekete, T., & Pázmándi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084190 · Cited by 117

Clinical Insights Into Novel Immune Checkpoint Inhibitors

Lee, J. B., Ha, S., & Kim, H. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681320 · Cited by 115

Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications

Vuong, J. T., Stein-Merlob, A. F., Nayeri, A., Sallam, T., Neilan, T. G., & Yang, E. H. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.048 · Cited by 116

A Janus Tale of Two Active High Mobility Group Box 1 (HMGB1) Redox States

Tang, D., Billiar, T. R., & Lotze, M. T. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00314 · Cited by 112

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

Ausejo‐Mauleon, I., Labiano, S., de la Nava, D., Laspidea, V., Zalacaín, M., Marrodán, L., García-Moure, M., González-Huarriz, M., Hervás-Corpión, I., Dhandapani, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.001 · Cited by 111

Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells

Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 117

The nature of activatory and tolerogenic dendritic cell-derived signal II

Bakdash, G., Sittig, S. P., van Dijk, T., Figdor, C. G., & de Vries, I. J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00053 · Cited by 126

Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions

Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113

Natural Killer Cells: Tumor Surveillance and Signaling

Guzman, L. G. M., Keating, N., & Nicholson, S. E. (2020) · Cancers · doi:10.3390/cancers12040952 · Cited by 118

Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?

Lentz, R. W., Colton, M. D., Mitra, S. S., & Messersmith, W. A. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0041 · Cited by 112

Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation

Phong, B. L., Avery, L., Sumpter, T. L., Gorman, J. V., Watkins, S. C., Colgan, J. D., & Kane, L. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150388 · Cited by 110

PD-1 Blunts the Function of Ovarian Tumor–Infiltrating Dendritic Cells by Inactivating NF-κB

Karyampudi, L., Lamichhane, P., Krempski, J. W., Kalli, K. R., Behrens, M. D., Vargas, D. M., Hartmann, L. C., Janco, J. M. T., Dong, H., Hedin, K. E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0748 · Cited by 113

Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy

İmani, S., Farghadani, R., Roozitalab, G., Maghsoudloo, M., Emadi, M., Moradi, A., Abedi, B., & Kaboli, P. J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03394-8 · Cited by 112

Combinatorial approach to cancer immunotherapy: strength in numbers

Vilgelm, A. E., Johnson, D. B., & Richmond, A. J. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 109

Molecular mechanisms involved in dendritic cell dysfunction in cancer

Tang, M., Diao, J., & Cattral, M. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2317-8 · Cited by 106

Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis

Jiang, X., Zhou, T., Xiao, Y., Yu, J., Dou, S., Chen, G., Wang, R., He, X., Hou, C., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1211219 · Cited by 106

Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization

Li, Z., Fu, W., Chen, X.-Q., Wang, S., Deng, R.-S., Tang, X., Yang, K., Niu, Q., Zhou, H., Li, Q., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02291-8 · Cited by 106

NK cells to cure cancer

Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 104

Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients

Jie, H.-B., Srivastava, R. M., Argiris, A. E., Bauman, J. E., Kane, L., & Ferris, R. L. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0333 · Cited by 103

Co-stimulatory and co-inhibitory pathways in cancer immunotherapy

O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 105

Tim-3 regulates sepsis-induced immunosuppression by inhibiting the NF-κB signaling pathway in CD4 T cells

Huang, S., Liu, D., Sun, J., Zhang, H., Zhang, J., Wang, Q., Gan, L., Qu, G., Qiu, J., Deng, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.12.013 · Cited by 101

Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

Mardi, A., Shirokova, A. V., Mohammed, R. N., Keshavarz, A., Zekiy, A. O., Thangavelu, L. P., Mohammad, T. A. M., Marofi, F., Shomali, N., Zamani, A., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02585-z · Cited by 102

Decoding immunogenic cell death from a dendritic cell perspective

Janssens, S., Rennen, S., & Agostinis, P. (2023) · Immunological Reviews · doi:10.1111/imr.13301 · Cited by 106

The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review

Mazzarella, L., Duso, B. A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., & Curigliano, G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.035 · Cited by 100

Cellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion

Verdon, D. J., Mulazzani, M., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197357 · Cited by 98

Novel strategies for cancer immunotherapy: counter-immunoediting therapy

Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects

Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., Bernardini, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091075 · Cited by 99

Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

Ebrahimi, N., Abdulwahid, A. R. R., Mansouri, A., Karimi, N., Bostani, R. J., Beiranvand, S., Adelian, S., Khorram, R., Vafadar, R., Hamblin, M. R., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05098-8 · Cited by 101

Oxidative Stress Elicits Platelet/Leukocyte Inflammatory Interactions via HMGB1: A Candidate for Microvessel Injury in Sytemic Sclerosis

Maugeri, N., Rovere, P. Q., Baldini, M., Baldissera, E. M., Sabbadini, M. G., Bianchi, M. E., & Manfredi, A. A. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5298 · Cited by 97

Emerging role of HMGB1 in lung diseases: friend or foe

Ding, J., Cui, X., & Liu, Q. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13048 · Cited by 95

Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives

Wang, J., Huang, X. F., & Li, F. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0387-3 · Cited by 97

Interactions between tumor-derived proteins and Toll-like receptors

Jang, G.-Y., Lee, J., Kim, Y. S., Lee, S., Han, H. D., Hong, K., Kang, T. H., & Park, Y. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00540-4 · Cited by 98

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade

Tian, T., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731175 · Cited by 100

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 95

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy

Yu, Y. (2023) · Cancers · doi:10.3390/cancers15082323 · Cited by 95

Inducible MicroRNA-3570 Feedback Inhibits the RIG-I-Dependent Innate Immune Response to Rhabdovirus in Teleost Fish by Targeting MAVS/IPS-1

Xu, T., Chu, Q., Cui, J., & Bi, D. (2017) · Journal of Virology · doi:10.1128/jvi.01594-17 · Cited by 93

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 95

Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8 + T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression

Clayton, K., Douglas-Vail, M. B., Rahman, A. K. M. N.-U., Medcalf, K. E., Xie, I. Y., Chew, G. M., Tandon, R., Lanteri, M. C., Norris, P. J., Deeks, S. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00006-15 · Cited by 92

Immune regulation by Tim-3

Banerjee, H., & Kane, L. (2018) · F1000Research · doi:10.12688/f1000research.13446.1 · Cited by 91

HMGB1 and repair: focus on the heart

Pellegrini, L., Foglio, E., Pontemezzo, E., Germani, A., Russo, M. A., & Limana, F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.005 · Cited by 92

Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells

Carenza, C., Calcaterra, F., Oriolo, F., Vito, C. D., Ubezio, M., Porta, M. G. D., Mavilio, D., & Bella, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01325 · Cited by 91

Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases

Huang, C., Zhu, H., Yao, Y., Bian, Z.-H., Zheng, Y.-J., Li, L., Moutsopoulos, H. Μ., Gershwin, M. E., & Lian, Z. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102333 · Cited by 94

The progression of HMGB1-induced autophagy in cancer biology

Xu, T., Jiang, L., & Wang, Z. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s185876 · Cited by 90

CD8+ T cell–derived IL-13 increases macrophage IL-10 to resolve neuropathic pain

Singh, S. K., Krukowski, K., Laumet, G. O., Weis, D., Alexander, J. F., Heijnen, C. J., & Kavelaars, A. (2022) · JCI Insight · doi:10.1172/jci.insight.154194 · Cited by 91

Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation

Kono, K., Mimura, K., & Kiessling, R. W. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.207 · Cited by 91

Tim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infection

Gorman, J. V., Starbeck-Miller, G. R., Pham, N., Traver, G. L., Rothman, P. B., Harty, J. T., & Colgan, J. D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302290 · Cited by 91

TIM-3 pathway dysregulation and targeting in cancer

Zeidan, A. M., Komrokji, R. S., & Brunner, A. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1865814 · Cited by 92

Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways

Rabinovich, G. A., & Conejo-Garcia, J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.03.021 · Cited by 92

A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease

Hansen, J. A., Hanash, S., Tabellini, L., Baik, C., Lawler, R. L., Grogan, B. M., Storer, B. E., Chin, A. P., Johnson, M. M., Wong, C., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.06.011 · Cited by 88

Metabolic Influences That Regulate Dendritic Cell Function in Tumors

Dong, H., & Bullock, T. N. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00024 · Cited by 89

Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy

Palanivelu, L., Liu, C., & Lin, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038226 · Cited by 86

Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases

Mackern‐Oberti, J. P., Llanos, C., Vega, F., Salazar‐Onfray, F., Riedel, C. A., Bueno, S. M., & Kalergis, A. M. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.010 · Cited by 83

The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases

Ge, Y., Huang, M., & Yao, Y.-M. (2021) · Cells · doi:10.3390/cells10051044 · Cited by 86

Beyond T cell exhaustion: TIM-3 regulation of myeloid cells

Dixon, K. O., Lahore, G. F., & Kuchroo, V. K. (2024) · Science Immunology · doi:10.1126/sciimmunol.adf2223 · Cited by 87

Role of Extracellular Damage-Associated Molecular Pattern Molecules (DAMPs) as Mediators of Persistent Pain

Kato, J., & Svensson, C. I. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2014.11.014 · Cited by 85

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

Cantoni, C., Huergo-Zapico, L., Parodi, M., Pedrazzi, M., Mingari, M. C., Moretta, A., Sparatore, B., Gonzalez, S. R., Olive, D., Bottino, C., et al. (2016) · Journal of Immunology Research · doi:10.1155/2016/4684268 · Cited by 85

Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress

Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 86

Regulation of T cell responses by the receptor molecule Tim-3

Gorman, J. V., & Colgan, J. D. (2014) · Immunologic Research · doi:10.1007/s12026-014-8524-1 · Cited by 83

Taming Dendritic Cells with TIM-3: Another Immunosuppressive Strategy Used by Tumors

Patel, J. M., Bozeman, E. N., & Selvaraj, P. (2012) · Immunotherapy · doi:10.2217/imt.12.126 · Cited by 45

Regulatory mechanisms of nucleic acid-mediated innate immune responses in the tumor microenvironment

Jinushi, M. (2012) · OncoImmunology · doi:10.4161/onci.21681 · Cited by 6

A Dendritic Cell-Derived Receptor Counteracts Antitumor Immunity

(2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2012-123

Tumor immunity times out: TIM-3 and HMGB1

Tang, D., & Lotze, M. T. (2012) · Nature Immunology · doi:10.1038/ni.2396 · Cited by 116

TIM3 suppresses antitumour DCs

Alderton, G. K. (2012) · Nature reviews. Immunology · doi:10.1038/nri3288 · Cited by 4